CHENGDU,
China, July 16, 2024 /PRNewswire/
-- "Evolving DNA-Encoded Library Technology and Its
Application for Innovative Drug Discovery" webinar will be jointly
hosted by HitGen Inc. and Xtalks on Wednesday July 17, 2024, at 2pm EDT (11am PDT).
Alex Shaginian, PhD, Vice President of Business Development
and Chemical Sciences, HitGen, David
Israel, PhD, Vice President of Lead Discovery Sciences,
HitGen; and Rusty Montgomery, PhD,
SVP-Research, BioAge Labs, will join the live webinar, and share
their insights into the challenges in drug discovery and different
selection strategies for DNA-encoded library (DEL) technology
in the drug discovery process. A detailed case study from BioAge on
the discovery of novel inhibitors using DEL technology will be
introduced.
![(PRNewsfoto/HitGen Inc.) (PRNewsfoto/HitGen Inc.)](https://mma.prnewswire.com/media/1768471/HitGen_Logo.jpg)
DEL technology has seen remarkable advancements in
recent years and has made a significant impact in successfully
identifying a variety of hit compounds that
have progressed to various stages of drug development.
Proteins are the major targets used in DEL
selection as they can be either extracted from biological
samples or, more often, expressed in the recombinant
form, which allows for different designs of protein constructs. DEL
technology presents a disruptive hit identification platform that
can vastly expedite the course of early-stage small-molecule drug
discovery.
In this free webinar, the expert speakers will provide an
introduction to free selection on different target types ranging
from enzymes to receptors and highlight the unique advantages
or features for the application of DELs on these targets. They will
also describe various DEL platforms that have been developed
and how they can be utilized to achieve success in the drug
discovery process.
Furthermore, as a case study, BioAge Labs will share
their experience in using DEL technology for their study
entitled "The discovery of novel and potent indazole NLRP3
inhibitors enabled by DNA-encoded library screening", which was
published in Bioorganic & Medicinal Chemistry
Letters. In this work, the researchers have demonstrated a
selection strategy for drug discovery using DEL, directly
identified small molecule structures, biophysical and biochemical
activities, physicochemical properties and other factors.
Register for this webinar to understand how DEL technology can
revolutionize small-molecule drug discovery.
For more information, or to register for this event, visit
Evolving DNA-Encoded Library Technology and Its Application for
Innovative Drug Discovery.
About HitGen
HitGen Inc. (SSE: 688222.SH), is a drug discovery research
company with headquarters in Chengdu,
China, and subsidiaries in Cambridge, UK and Houston, USA.
HitGen has established leading technology platforms to enable the
discovery and optimization of small molecules and nucleic acid
drugs. Our key technology platforms include world-leading
DNA-encoded library technology (DEL), fragment-based drug discovery
and structure-based drug design technologies (FBDD/SBDD), as well
as the emerging technology platforms for synthetic therapeutic
oligonucleotide technology (STO), and targeted protein degradation
technology (TPD). Through our diverse and flexible business models,
we have built up collaboration partnership with several hundred
biopharmaceutical research organizations worldwide. HitGen has
multiple programmes from early discovery to clinical trial
stage.
CONTACT
Brian Moloney |
Chief Business Officer | +1-760-644-8468 |
brian.moloney@hitgen.com.
Alex Shaginian | VP Business
Development & Chemical Sciences | +1-608-213-5682 |
alex.shaginian@hitgen.com.
Email: bd@hitgen.com
Or visit www.hitgen.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/evolving-dna-encoded-library-technology-and-its-application-for-innovative-drug-discovery-upcoming-webinar-hosted-by-hitgen-and-xtalks-302198355.html
SOURCE HitGen Inc.